What is a clinical trial and why it matters
What is a clinical trial?
A clinical trial is a research study that explores how new treatments work and whether they are safe and could benefit patients. Fate Therapeutics is currently enrolling for clinical trials for CAR T-cell therapy treatment.
Advancing research.
By taking part in Fate’s CAR T-cell clinical trials, you may help researchers learn more about your condition and contribute to advances that could benefit future patients.
Access to innovative treatment.
Fate’s CAR T-cell therapy is being researched as a new potential option for patients whose current treatments are not working.
Fate Therapeutics is currently recruiting patients living with either certain autoimmune diseases or cancer types for CAR T-cell therapy trials.
For additional information or to inquire about participating in any of Fate’s clinical trials please contact: clinicaltrials@fatetherapeutics.com or download our patient brochure
Patient Journeys
Experience what participating in a CAR T-cell therapy clinical trial for Lupus may be like for you
Nebraska Medicine uses cutting-edge cell therapy to treat lupus for first time
A decade of suffering has given way to a new lease on life for an Omaha mother with lupus. Learn more here.
Omaha woman, who has suffered with lupus pain, finding relief after receiving novel therapy
Omaha mother of twins Lauren Koop Daughtrey underwent a newer type of CAR T-cell therapy to target her lupus this spring in a clinical trial at the University of Nebraska Medical Center. Learn more here.
FT819-102 Study
Condition: Autoimmune Diseases
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
For additional information or to inquire about participating in the FT819-102 clinical trial please contact us.
Participation Expectations
Study Locations (17)
United States
Los Angeles, California, 90027
Children’s Hospital Los Angeles Division Of Rheumatology
San Francisco, California, 94110
University of California San Francisco
Minneapolis, Minnesota, 55455
University of Minnesota Medical School
Philadelphia, Pennsylvania, 19141
Jefferson Einstein Hospital Philadelphia
France
Sweden
United Kingdom
Cambridge, CB2 0QQ
Cambridge University Hospitals NHS Foundation Trust
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Condition: Cancer
This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.
Participation Expectations
FT825-101 Study
Condition: Cancer
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.
For additional information or to inquire about participating in the FT825-101 clinical trial please contact us.
Participation Expectations
Study Locations (14)
United States
La Jolla, California, 92037
University of California San Diego Moores Cancer Center
New Haven, Connecticut, 06510
Yale New Haven Hospital – Yale Cancer Center
Minneapolis, Minnesota, 55455
University of Minnesota Medical School
St Louis, Missouri, 63110
Washington University School of Medicine
Columbus, Ohio, 43210
Ohio State University – Comprehensive Cancer Center
Philadelphia, Pennsylvania, 19107
Thomas Jefferson University, Sidney Kimmel Cancer Center